

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 1, 2001, 16:18:24 ; Search time 64.32 Seconds
(Without alignments)
14.885 Million cell updates/sec

Title: US-09-331-631A-32

Perfect score: 76
Sequence: 1 CXXCXXCXXXXXXXXXXCXXCXXC 28

Scoring table: BLOSUM62DX
Gapop 10.0 , Gapext 0.5

Searched: 268485 segs, 34193795 residues

Total number of hits satisfying chosen parameters: 268485

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_36.*
1: /SIDSL/gcgdata/geneseq/AA1980.DAT:*
2: /SIDSL/gcgdata/geneseq/AA1981.DAT:*
3: /SIDSL/gcgdata/geneseq/AA1982.DAT:*
4: /SIDSL/gcgdata/geneseq/AA1983.DAT:*
5: /SIDSL/gcgdata/geneseq/AA1984.DAT:*
6: /SIDSL/gcgdata/geneseq/AA1985.DAT:*
7: /SIDSL/gcgdata/geneseq/AA1986.DAT:*
8: /SIDSL/gcgdata/geneseq/AA1987.DAT:*
9: /SIDSL/gcgdata/geneseq/AA1988.DAT:*
10: /SIDSL/gcgdata/geneseq/AA1989.DAT:*
11: /SIDSL/gcgdata/geneseq/AA1990.DAT:*
12: /SIDSL/gcgdata/geneseq/AA1991.DAT:*
13: /SIDSL/gcgdata/geneseq/AA1992.DAT:*
14: /SIDSL/gcgdata/geneseq/AA1993.DAT:*
15: /SIDSL/gcgdata/geneseq/AA1994.DAT:*
16: /SIDSL/gcgdata/geneseq/AA1995.DAT:*
17: /SIDSL/gcgdata/geneseq/AA1996.DAT:*
18: /SIDSL/gcgdata/geneseq/AA1997.DAT:*
19: /SIDSL/gcgdata/geneseq/AA1998.DAT:*
20: /SIDSL/gcgdata/geneseq/AA1999.DAT:*
21: /SIDSL/gcgdata/geneseq/AA2000.DAT:*

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	76	100.0	31	21	Y70731
2	67	88.2	57	21	Wnt antagonist pro
3	67	88.2	76	17	Carb metallothione
4	67	88.2	77	17	Hawskbill turtle s
5	67	88.2	77	18	Hawskbill turtle s
6	67	88.2	79	21	Tortoise shell sur
7	67	88.2	109	17	Human 5' EST relat
8	67	88.2	110	21	T-Lymphocyte stimu
9	67	88.2	115	20	Human epidermal pr
10	67	88.2	135	21	Drosophila Acp62p
11	67	88.2	138	13	Human secreted pro
12	67	88.2	149	8	CA455 protein. Ze
					Human insulin rece

13	67	88.2	169	20	Y60558	Human normal blad
14	67	88.2	246	19	W53007	Mus musculus I-mfa
15	67	88.2	516	18	W15286	Soluble type I ins
16	67	88.2	560	12	R15051	Hybrid human insul
17	67	88.2	624	11	R08222	Extracellular port
18	67	88.2	690	19	W77414	Human sodium depen
19	67	88.2	782	18	W19764	Her2-GM-CSF immuno
20	67	88.2	906	20	W18133	Human insulin-like
21	67	88.2	934	12	R14402	Soluble insulin-li
22	67	88.2	934	12	R15048	Soluble human IGF-
23	67	88.2	935	12	R15050	Hybrid human insul
24	67	88.2	948	12	R14403	Extracellular doma
25	67	88.2	948	12	R15049	Hybrid human insul
26	67	88.2	951	21	Y44993	DCscf-erbB2EC fu
27	67	88.2	956	12	R15047	Soluble human insu
28	67	88.2	1214	21	Y79152	Mouse protein kina
29	67	88.2	1255	17	W01111	HER-2/neu protein.
30	67	88.2	1255	20	W92406	Human HER-2/neu on
31	67	88.2	1255	21	Y84780	Amino acid sequenc
32	67	88.2	1255	21	Y92620	Human heregulin 2
33	67	88.2	1337	15	R63123	IGF-I receptor 943
34	67	88.2	1337	15	R63124	IGF-I receptor 950
35	67	88.2	1337	15	R63125	IGF-I receptor 957
36	67	88.2	1337	15	R63126	IGF-I receptor 100
37	67	88.2	1367	15	R60795	Human IGF-1 recept
38	67	88.2	1367	15	R63122	IGF-I receptor. H
39	67	88.2	1367	17	R95244	IGF-I receptor. H
40	67	88.2	1367	17	R91429	Human type I insul
41	67	88.2	1367	18	W37692	Human insulin-like
42	67	88.2	1367	19	W34876	Homo sapiens IGF-I
43	67	88.2	1370	7	P60005	Sequence encloded b
44	67	88.2	1370	17	R91430	Rat type I insulin
45	67	88.2	1382	17	R77440	Wild type human in

ALIGNMENTS

RESULT	1
ID	Y70731 standard; protein; 31 AA.
XX	
AC	Y70731;
XX	
DT	24-JUL-2000 (first entry)
XX	
DE	Wnt antagonist protein consensus sequence-1.
XX	
KW	Wnt antagonist; contraceptive; contraceptive vaccine; oocyte development;
KW	female primate contraception; oocyte viability.
XX	
OS	Synthetic.
XX	
FH	Key
FT	Misc-difference 2
FT	/label= Unknown
FT	/note= "Xaa may be 9 amino acids in length; some
FT	amino acids may be absent"
FT	Misc-difference 4
FT	/label= Unknown
FT	/note= "Xaa may be 42 amino acids in length; some
FT	amino acids may be absent"
FT	Misc-difference 14
FT	/label= Unknown
FT	Misc-difference 15
FT	/label= Unknown
FT	Misc-difference 16
FT	/label= Unknown
FT	Misc-difference 17
FT	/label= Unknown
FT	Misc-difference 18
FT	/label= Unknown
FT	Misc-difference 19

FT	/label= Unknown
FT	Misc-difference 21
FT	/label= Unknown
FT	/note= "Xaa may be 10 amino acids in length; some amino acids may be absent"
FT	Misc-difference 23
FT	/label= Unknown
FT	Misc-difference 24
FT	/label= Unknown
FT	Misc-difference 25
FT	/label= Unknown
FT	Misc-difference 27
FT	/label= Unknown
FT	/note= "Xaa may be 7 amino acids in length; some amino acids may be absent"
FT	Misc-difference 29
FT	/label= Unknown
FT	/note= "Xaa may be 27 amino acids in length; some amino acids may be absent"
FT	Misc-difference 31
FT	/label= Unknown
FT	/note= "Xaa may be 13 amino acids in length; some amino acids may be absent"
PN	WO20021555-A1.
PD	20-APR-2000.
PF	13-OCT-1999; 99WO-US23640.
PR	15-OCT-1998; 98US-0104355.
PA	(HARD) HARVARD COLLEGE.
PI	McMahon AP, Parr BA, Vaino S;
DR	WPI: 2000-317845/27.
PT	Contraceptive composition for inhibiting oocyte development in a female primate comprises a Wnt polypeptide antagonist -
PS	Claim 12; Page 44; 57pp; English.
CC	The patent discloses a method of female primate contraception comprising administering an antagonist of a Wnt polypeptide, inhibiting oocyte development. Wnt polypeptides are useful for promotive maturation of an immature oocyte. Wnt polypeptides are also useful for increasing the number of mature oocytes and to enhance oocyte viability. The present peptide is a consensus sequence of Wnt antagonist which inhibits the physiological activity of a Wnt polypeptide. Antagonistic polypeptides may contain a cysteine-rich domain.
SQ	Sequence 31 AA;
OY	Query Match 100.0%; Score 76; DB 21; Length 31; Best Local Similarity 67.9%; Pred No 7.6; Matches 19; Conservative 9; Mismatches 0; Indels 0; Gaps 0 1 CXXCXXXCXKXXXXXXXXXXXXXCNXXCXKXC 28 :: :: :: :: :: :: :: :: :: :: : Db 3 CXCCCCCCCXXXXXXXXXXCXKXCXC 30
RESULT 2	
ID Y57813	Y57813 standard; protein: 57 AA.
AC Y57813:	
DT 22-MAR-2000	(first entry)
DE Crab metallothionein Class I amino acid sequence.	

[illegible]

RESULT 6
 ID Y64946 standard; Protein: 79 AA.
 AC Y64946;
 DT 01-FEB-2000 (first entry)
 DE Human 5' EST related polypeptide SEQ ID NO:1107.
 XX
 KM Human; 5' EST; expressed sequence tag; secreted protein; diagnosis;
 KM gene therapy; chromosome mapping; upstream regulatory sequence;
 KM forensic; location; development; protein synthesis; stability;
 KM regulation; identification.
 XX
 OS Homo sapiens.
 PN WO953051-A2.
 XX
 PD 21-OCT-1999.
 XX
 PF 09-APR-1999; 99MO-IB00712.
 XX
 PR 09-APR-1998; 98US-0057719.
 PR 28-APR-1998; 98US-0069047.
 XX
 PA (GEST) GENSET.
 PI Dumas Milne Edwards J, Duclert A, Giordano J;
 DR WPI: 2000-038446/03.
 DR N-PSDB: 242560.
 XX
 PT Novel secreted protein 5' expressed sequence tag sequences used in
 PT diagnostic, forensic, gene therapy, and chromosome mapping procedures
 XX
 PS Claim 3; Page 688: 837pp; English.
 XX
 CC 242265 to 243075 represent novel 5' expressed sequence tag (EST)
 CC sequences, corresponding to human secreted proteins. Y64651 to Y65438
 CC represent the EST-related proteins corresponding to 242265 to 243052.
 CC The 5' ESTs can be used for producing secreted human gene products.
 CC They can be used to identify and isolate 5' untranslated regions (UTRs)
 CC and upstream regulatory regions which control the location, development
 CC stage, rate, and quantity of protein synthesis, as well as stability of
 CC mRNA. The ESTs are also useful as probes for chromosome mapping, and to
 CC obtain full length cDNA clones. The ESTs can also be used in forensic
 CC procedures to identify individuals, or in diagnostic procedures to
 CC identify individuals having genetic diseases resulting from abnormal
 CC gene expression. The products may also be used in gene therapy protocols.
 CC The nucleic acids encoding signal peptides can be used for directing
 CC extracellular secretion of a polypeptide or the insertion of a
 CC polypeptide into a membrane, or importing a polypeptide into a cell.
 CC The proteins encoded by the EST sequences may be useful in treating a
 CC variety of human conditions. Secreted proteins have therapeutic value,
 CC and the identification of new secreted proteins is valuable. 242249 to
 CC 242264 and Y64644 to Y64650 represent sequences used in the
 CC exemplification of the present invention.
 XX
 SO Sequence 79 AA:

XX	RESULT	7
XX	R84086	
XX	ID	R84086 standard; Protein: 109 AA.
XX	AC	R84086;
XX	DT	28-NOV-1996 (first entry)
XX	DE	T-lymphocyte stimulatory protein.
XX	KW	E. maxima; T-lymphocyte stimulatory protein; Elimeria; protozoan;
XX	KW	coccidiosis; chicken; vaccine; poultry; probe.
XX	OS	Elimeria maxima.
XX	PN	AU9531720-A.
XX	PD	28-MAR-1996.
XX	PF	15-SEP-1995; 95AU-0031720.
XX	PR	16-SEP-1994; 94EP-0202676.
XX	PA	(ALKU) AKZO NOBEL NV.
XX	PI	Bumstead JM, Dunn PPJ, Tomley FM, Vermeulen AN;
XX	DR	WPI; 1996-210114/22.
XX	DR	N-PSDB; T14351.
XX	PT	DNA encoding Elimeria T-lymphocyte stimulatory protein - used in
XX	PT	vaccines to protect poultry against coccidiosis, and to develop
XX	PT	prods. for diagnosis of Elimeria infection
XX	PS	Claim 1; Page 46; 59pp; English.
XX	CC	This sequence represents E. maxima T-lymphocyte stimulatory protein.
XX	CC	Elimeria protozoans are the cause of coccidiosis in chickens. The DNA
XX	CC	encoding this sequence may be attached to a suitable promoter and used
XX	CC	in a recombinant vector in the production of a vaccine for the protection
XX	CC	of poultry against coccidiosis. Fragments of this sequence may also
XX	CC	be used as probes to detect Elimeria-related nucleic acid in tissue.
XX	CC	Due to poor print quality in the specification, this sequence is a
XX	CC	"best guess" based on the corresponding DNA sequence.
XX	Sequence	109 AA;

	Query Match	88.2%;	Score 67;	DB 17;	Length 109;
	Best Local Similarity	18.5%;	Pred. No.	1.2e+02;	
	Matches	5;	Conservative	22;	Mismatches 0; Indels 0; Gaps 0
Oy	2 xxcxxxcxxxxxxxxxxcxxxccxxxc	28	::::: :::::::::: ::::		
Db	27 kccscckccskccscstycctfcacsk	53			
RESULT	8				
ID	y44986				
XX	y44986 standard; Protein; 110 AA.				
XX	AC				
XX	y44986;				
DT	23-MAY-2000 (first entry)				
DE	Human epidermal protein-3.				
XX					
KW	Human epidermal protein-3; HEP1; epithelial disorder; scabies;				
KW	dysidrotic eczema; cell proliferative disorder; actinic keratosis;				
KW	arteriosclerosis; autoimmune disorder; inflammatory disorder;				
KW	acquired immune deficiency syndrome; AIDS; Addison's disease; antiHIV;				
KW	dermatological; antiatherosclerotic; antiInflammatory;				
KW	immunosuppressive.				

XX OS Homo sapiens.
XX
XX Key Location/Qualifiers
FH Modified-site 21
FT /note= "Potential phosphorylation site"
FT 66.09
FT Modified-site /note= "Glycosaminoglycan attachment site"
XX
XX WO200006727-A2.
XX
XX PD 10-FEB-2000.
XX
XX PF 27-JUL-1999; 99WO-US17107.
XX
XX PR 28-JUL-1998; 98US-0155203.
XX
XX PR 07-DEC-1998; 98US-0155254.
XX
XX PA (INCYTE) INCYTE PHARM INC.
XX
XX PI Tang YT, Lal P, Corley NC, Guegler KJ, Patterson C, Baughn MR;
XX
XX PI Yue H;
XX
XX DR MPI: 2000-195295/17.
XX
XX DR N-PSDB; Z50579.
XX
XX PT New human epidermal proteins (HEPI-1) to (HEPI-6) useful for the
XX
XX PT diagnosis, treatment and prevention of epithelial, cell proliferative,
XX
XX PT and autoimmune inflammatory disorders
XX
XX PS Claim 1; Fig 1; 82pp; English.
XX
XX CC The present sequence is human epidermal protein-3 (HEPI) expressed in
XX
XX CC proliferating skin tissues. This protein is derived from COLNOR27 CDNA
XX
XX CC library and comprises small proline-rich protein repeats. HEPI-3 shares
XX
XX CC 95% identity with human skin specific protein. Recombinant vectors
XX
XX CC comprising HEPI cDNA are introduced into host cells for protein
XX
XX CC expression. The HEPI proteins are useful for the treatment of epithelial
XX
XX CC disorders, including dysidrotic eczema and scabies, cell proliferative
XX
XX CC disorders including actinic keratosis and arteriosclerosis, and
XX
XX CC autoimmune/inflammatory disorders like acquired immune deficiency
XX
XX CC syndrome (AIDS) and Addison's disease. Pharmaceutical compositions
XX
XX CC comprising HEPI proteins are useful for treating disorders associated
XX
XX CC with altered HEPI expression.
XX
XX SQ Sequence 110 AA;

Query Match 88.2%; Score 67; DB 21; Length 110;
Best Local Similarity 18.5%; Pred. No. 1.3e+02;
Matches 5; Conservative 22; Mismatches 0; Indels 0; Gaps 0;

OY 2 XXCXXXXXXXXXXXXXXXXCXXC 28
DB 14 PKCPCPCPCPCPCPCPCPCPCPC 40

RESULT 9
Y22170
ID Y22170 standard; Protein: 115 AA.
XX
XX AC Y22170;
XX
XX DT 09-SEP-1999 (first entry)
XX
XX DE Drosophila Acp62F protein.
XX
XX KW Accessory gland protein; Acp; toxin; insecticide; Drosophila; mating;
XX
XX KW caterpillar; development inhibitor; insect pest; plant protection.
XX
XX OS Drosophila melanogaster.
XX
XX PN WO932149-A1.

XX PD 01-JUL-1999.
XX
XX PF 23-DEC-1998; 98WO-US27603.
XX
XX PR 23-DEC-1997; 97US-0071315.
XX
XX PA (CORR) CORNELL RES FOUND INC.
XX
XX PI Lung O, Tram K, Wolfner MF;
XX
XX PI MPI: 1999-418671/35.
XX
XX DR N-PSDB; X84363.
XX
XX DR Nucleic acid encoding accessory gland proteins of Drosophila
XX
XX PT Claim 20; Page 12; 89pp; English.
XX
XX PS This sequence is a Drosophila melanogaster accessory gland protein
XX
XX CC (Acp) of the invention. A particular Acp, designated Acp62F, is toxic to
XX
XX CC insects, particularly to Drosophila and caterpillars, and it (or vectors
XX
XX CC that express it) can be used to kill or inhibit development of insect
XX
XX CC pests, for plant protection. More generally detection of Acp's in a
XX
XX CC female fruit fly is indicative of recent mating.
XX
XX SQ Sequence 115 AA;

Query Match 88.2%; Score 67; DB 20; Length 115;
Best Local Similarity 18.5%; Pred. No. 1.3e+02;
Matches 5; Conservative 22; Mismatches 0; Indels 0; Gaps 0;

OY 2 XXCXXXXXXXXXXXXXXXXCXXC 28
DB 41 tccpvcpcpcpcpcpcpcpcpcpc 67

RESULT 10
Y91429
ID Y91429 standard; Protein: 135 AA.
XX
XX AC Y91429;
XX
XX DT 29-JUN-2000 (first entry)
XX
XX DE Human secreted protein sequence encoded by gene 21 SEQ ID NO:150.
XX
XX KW Human; secreted protein; diagnosis; neuroprotective; nootropic;
XX
XX KW neuroleptic; antianemic; cerebroprotective; immunomodulatory;
XX
XX KW anti-microbial; cardiatic; cytosatic; antiinflammatory; haemostatic;
XX
XX KW anticonvulsant; vasotropic; vaccine; gene therapy; anti-sense therapy;
XX
XX KW neural; reproductive; immune disorder; immunodeficiency; infection;
XX
XX KW lymphoma; demyelinating disease; autoimmune; cancer; inflammation;
XX
XX KW aneurysm; haemorrhage; Alzheimer's disease; Parkinson's disease;
XX
XX KW Huntington's disease; Tourette syndrome; multiple sclerosis; meningitis;
XX
XX KW ischaemia; mania; dementia; obsessive compulsive disorder;
XX
XX KW viral prophylaxis; developmental disorder; sexually-linked disorder;
XX
XX KW cardiovascular disorder; food additive; preservative.
XX
XX OS Homo sapiens.
XX
XX PN WO200011014-A1.
XX
XX PD 02-MAR-2000.
XX
XX PF 24-AUG-1999; 99WO-US19330.
XX
XX PR 25-AUG-1998; 98US-0097917.
XX
XX PR 31-AUG-1998; 98US-0096634.
XX
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX
XX PI Moore PA, Ruben SM, Olsen HS, Shi Y, Rosen CA, Florence KA;

PI Soppet DR, Lafleur DW, Endress GA, Ebner R, Komatsoulis G;
PI Dian RD;
XX
XX WPI: 2000-224656/19.
XX
XX Novel secreted proteins and corresponding DNA molecules that can be
PT used to prevent, treat and diagnose disease in humans, for example,
PT Alzheimer's, cancer, and immune disorders -
XX
PS Disclosure: Page 403; 416pp; English.
XX
XX The polynucleotide sequences given in A26281 to A26336 encode the human
CC secreted proteins given in Y9146 to Y9149. The human secreted proteins
CC can have activities based on the tissues and cells they are expressed in.
CC Examples of the activities are: neuroprotective; neurotropic; neuroleptic;
CC antiangiogenic; cerebroprotective; immunomodulatory; antimicrobial; cardiatic;
CC cyostatic; antinflammatory; haemostatic; anticoagulant; and
CC vasotropic. The polynucleotides and proteins may be used to prevent,
CC treat or ameliorate a medical condition, e.g. by protein or gene therapy.
CC Conditions treatable by the proteins of the invention include: neural,
CC reproductive, or immune disorders, especially immunodeficiency,
CC infection, lymphomas, demyelinating diseases, auto-immunities, cancer,
CC general microbial infection, inflammation, aneurysms and haemorrhages.
CC Specific examples include: Alzheimer's disease; Parkinson's;
CC Huntington's; Tourette syndrome; multiple sclerosis; meningitis;
CC ischaemia; prostate cancer; mania; dementia; obsessive compulsive
CC disorder and viral prophylaxis. The polynucleotides and proteins can also
CC be used in the detection of disorders associated with the function of the
CC protein, for example, the detection of developmental disorders,
CC sexually-linked disorders, or disorders of the cardiovascular system.
CC They may also be used as food additives or preservatives. A26272 to
CC A26280 and Y9145 are sequences used in the exemplification of the
CC present invention.
XX
XX Sequence 135 AA:
XX

Query Match	88.2%	Score 67	DB 21	Length 135
Best Local Similarity	18.5%	Pred. No. 1.5e+02		
Matches	5	Conservative	22	Mismatches 0; Indels 0; Gaps 0

Qy	2	XXXXXXXXXXXXXXXXXXXXXX	28
		:: :: :: :: :: :: :: ::	
Db	13	gmcmcvcacvyacmlmhvcvhaclvc	39

RESULT	11
R26820	
ID	R26820 standard; Protein; 138 AA.

AC	R26820;
XX	
DT	10-FEB-1993 (first entry)

CA455 protein.

KW Corn; stamen-specific; tassel spikelets; CA444; CA455; probe; PCR;
KW amplify.

05 Zee mays.

PN W09213957-A.

PD 20-AUG-1992.

PF 05-FEB-1992; 92WO-EP00275.

PR 07-FEB-1991; 91EP-0400300.

PR 28-JUN-1991; 91EP-0401787.

PA (PLBZ) PLANT GENETIC SYSTEMS NV.

PI De Beuckeleer M, Gossele V, Herdies L, Mariani C;

xx WPI: 1992-300043/36.
DR N-PSDB: Q27949.
xx
xx Anther-specific promoters - for control of expression of
PT male-sterile or male fertility-restorer DNA in monocots e.g.
PT wheat or corn
xx
xx
PS Disclosure; Page 31-33; 4pp; English.
xx
xx The sequence given is encoded by a male flower-specific cDNA sequence
CC isolated from corn. The cDNA sequence was isolated by using probes
CC based on the gene core region. The cDNA sequence can be used in a
CC foreign, chimeric DNA sequence containing a male-sterility DNA or a
CC male-fertility restorer DNA under the transcriptional control of the
CC promoter sequence. This vector can be used to transform the nuclear
CC genome of a cell of a plant.
xx
xx Sequence 138 AA:
SO

Query Match	88.2%	Score 67	DB 13	Length 136
Best Local Similarity	18.5%	Pred. No.	1.5e+02	
Matches	5	Conservative	22	Mismatches 0
				Indels 0
				Gaps 0

```
QY 2 XXXXXXXXXXXXXXXXXXXX 28
    ::::::::::::::::::::|
Db 112 mlcgkgtlshskcaakctkscvptc 138
```

RESULT	12
P70057	
ID	P70057 standard; protein; 149 AA.

AC P70057;

DT 27-JAN-1991 (first entry)

Human insulin receptor.

KW Furlin; insulin receptor; tumor diagnosis.

OS Homo sapiens.

PN EP246709-A.

PD 25-NOV-1987

PF 19-MAY-1987; 87EP-0200940.

PR 20-MAY-1986; 86NL-0001271.

PA (UYKA-) KATHOLIEKE UNIV.
VY

PI Van de Ven WJM;

PI Schalken JA;

DR WPI; 1987-328946/47.

PT Recombinant DNA containing the fur gene - used for producing furin
PT protein and antibodies and as a diagnostic aid in the detection of
PT tumours.

PS Disclosure; Fig 10; 24pp; English.

CC The sequence of the human insulin receptor is provided for
CC comparison with the cysteine-rich region of furin. Furin
CC is strongly expressed in specific types of tumors and
CC labelled RNA or DNA probes of the fur gene and antibodies
CC against furin can be used for diagnostic purposes.
CC (see also N70061, N70062, N70060, P70056 and P70055)

```

SQ      Sequence      149 AA:

Query Match      88.2%:  Score 67:  DB 8:  Length 149:
Best Local Similarity 18.5%:  Pred. No. 1.7e+02:
Matches      5:  Conservative      22:  Mismatches      0:  Indels      0:  Gaps      0:

OY      2 XXXXXXXXXXXXXXXXXXXXCCXXCCXXCC 28
      :|::|::|::|::|::|::|::|::|::|::|::|
Db      7 kvcpickshgctaaglcchseclgnc 33

RESULT 13
ID      Y60558 standard; Protein: 169 AA.
XX      Y60558;
AC      Y60558;
XX      31-JAN-2000 (first entry)
DT
XX
XX      Human normal bladder tissue EST encoded protein 230.
DE
XX      Human; bladder; treatment; EST; expressed sequence tag; cytostatic;
KW      cancer; gene therapy.
XX      Homo sapiens.
OS
XX      DE19818620-A1.
PN
XX      28-OCT-1999.
PD
XX      21-APR-1998; 98DE-1018620.
PF
XX      21-APR-1998; 98DE-1018620.
PR
XX      (META-) METAGEN GES GENOMFORSCHUNG MBH.
PA
XX      Rosenthal A, Specht T, Hinzmann B, Schmitt A, Pilarsky C, Dahl E;
PI
XX      MPI: 1999-602416/52.
DR      N-PSDB: Z42235.
XX
XX      New polypeptides and their nucleic acids, useful for treatment of
PT      bladder tumour and identification of therapeutic agents -
PR
XX
XX      Claim 23; Page 338; 366pp; German.
PS
XX
XX      This invention describes novel polypeptide fragment sequences (I) and
CC      their encoding nucleic acids (II) which are highly expressed in normal
CC      bladder tissue and have cytosstatic activity. (II) are used for
CC      recombinant expression of (I) and to isolate complete genes. (I) are
CC      used to identify agents suitable for the treatment of bladder tumours, to
CC      directly treat this form of cancer (including expression from gene
CC      therapy vectors), or are used in a preparation for cancer treatment. (I)
CC      is also used for the generation of specific antibodies. (II) are
CC      identified by assembling ESTs (expressed sequence tags) from a particular
CC      tissue type before comparison of expression patterns. This allows a
CC      significantly longer fragment of the gene to be revealed, and therefore
CC      reduces the number of failures because of ESTs from different libraries
CC      representing different parts of the same unknown gene distorting the
CC      estimated frequency of occurrence in a particular tissue. Y60329-Y60591
CC      represent protein fragments encoded by the human normal bladder tissue
CC      cDNA library derived EST fragments represented in Z42122-Z42248.
XX
XX      Sequence      169 AA:

Query Match      88.2%:  Score 67:  DB 20:  Length 169;
Best Local Similarity 18.5%:  Pred. No. 1.9e+02:
Matches      5:  Conservative      22:  Mismatches      0:  Indels      0:  Gaps      0:

OY      2 XXXXXXXXXXXXXXXXXXXXCCXXCCXXCC 28
      :|::|::|::|::|::|::|::|::|::|::|::|

```

```

Db      57  sgcgccggppltlpwqracgdcwasc 83

RESULT  14
W53007
ID      W53007 standard; Protein; 246 AA.
XX
AC      W53007;
XX
DF      03-AUG-1998 (first entry)
XX
DE      Mus musculus I-mfa protein.
XX
KW      I-mfa; inhibitor of MyoD family; treatment; diagnosis; myogenesis;
KW      defects; abnormal development; disease; cleidocranial dysplasia;
KW      CDD; rhabdomyosarcoma; muscle tissue cancer.
XX
OS      Mus musculus.
XX
PN      W09808860-A1.
XX
PD      05-MAR-1998.
XX
PF      21-AUG-1997; 97WO-US14780.
XX
PR      27-AUG-1996; 96US-0704931.
XX
PA      (HUTC-) HUTCHINSON CANCER RES CENT FRED.
PI      Chen CMA, Groudine M, Kraut N, Weintraub H;
DR      WPI; 1998-179377/16.
DR      N-PSDB; V21282.
XX
PT      Inhibitor of MyoD family proteins - useful for, e.g. treatment and
PT      diagnosis of defects in myogenesis responsible for abnormal
PT      development
XX
XX      Disclosure; Pages 74-75; 92pp; English.
XX
CC      The sequence is that of murine I-mfa (inhibitor of MyoD family)
CC      protein. Probes from the gene sequence can be used for determining the
CC      presence of an I-mf protein or analogue, or for detecting I-mf
CC      agonist activity in a test substance. The sequence can be used
CC      for a short, model and diagnose defects in myogenesis responsible
CC      for abnormal development and disease conditions in mammals,
CC      including humans. These include the human disease cleidocranial
CC      dysplasia (CDD), rhabdomyosarcomas and other cancers affecting
CC      muscle tissue in mammals.
XX
SQ      Sequence      246 AA;

Query Match      88.2%; Score 67; DB 19; Length 246;
Best Local Similarity 18.5%; Pred. No. 2.7e+02;
Matches 5; Conservative 22; Mismatches 0; Indels 0; Gaps 0;

QY      2 XXXCXXXCXXXXXXXXXXCXXCXXCXXC 28
      :|::|::|::|::|::|::|::|::|::|
DB      214 lpcddcgivdacesadcleimcc 240

RESULT  15
W15286
ID      W15286 standard; Protein; 516 AA.
XX
AC      W15286;
XX
DT      06-AUG-1997 (first entry)
XX
DE      Soluble type I insulin-like growth factor receptor.
XX
KW      Type I insulin-like growth factor receptor; IGF-1R; tumour;

```

